This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coulson, J. M. Articles by Quinn, J. P. Search for Related Content PubMed PubMed Citation Articles by Coulson, J. M. Articles by Quinn, J. P.

A Splice Variant of the Neuron-restrictive Silencer Factor Repressor Is Expressed in Small Cell Lung Cancer: A Potential Role in Derepression of Neuroendocrine Genes and a Useful Clinical Marker¹

Cancer Research Campaign Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Nottingham NG5 1PB [J. M. C., J. L. E., P. J. W.], and Veterinary Pathology, University of Edinburgh, Summerhall, Edinburgh, EH9 1QH [J. P. Q.], United Kingdom

The neuron-restrictive silencer factor [NRSF (RE-1 silencing transcription factor/X box repressor)] is a transcriptional silencer, which we have previously implicated in deregulation of the vasopressin promoter in small cell lung cancer (SCLC). Here we describe a novel splice variant of the NRSF transcript, which is highly expressed in SCLCs. The variant was detected in both established cell lines and primary SCLC cultures as well as in some primitive neuroectodermal tumor biopsies. It was present at very low levels in human brain tissue, non-SCLC tumors, and normal bronchial epithelium. This human splice variant, which is massively overexpressed in SCLCs, incorporates a 50-bp insert between exons 5 and 6, introducing a stop codon and predicting translation of a truncated NRSF isoform. We propose that the encoded isoform may antagonize repression of the vasopressin promoter and other "neuronal" genes with neuron- restrictive silencer elements in SCLCs. Thus, up-regulated expression of this NRSF isoform may be a key early factor in defining the neuroendocrine phenotype of these tumors. The NRSF splice variant represents a specific clinical marker that could prove useful in detection of the majority of SCLCs.

This article has been cited by other articles:

				R. M. Donev, L. C. Gray, B. Sivasankar, T. R. Hughes, C. W. van den Berg, and B. P. Morgan Modulation of CD59 Expression by Restrictive Silencer Factor-Derived Peptides in Cancer Immunotherapy for Neuroblastoma Cancer Res., July 15, 2008; 68(14): 5979 - 5987. [Abstract] [Full Text] [PDF]

				S. J. Otto, S. R. McCorkle, J. Hover, C. Conaco, J.-J. Han, S. Impey, G. S. Yochum, J. J. Dunn, R. H. Goodman, and G. Mandel A New Binding Motif for the Transcriptional Repressor REST Uncovers Large Gene Networks Devoted to Neuronal Functions J. Neurosci., June 20, 2007; 27(25): 6729 - 6739. [Abstract] [Full Text] [PDF]

				P. Olguin, P. Oteiza, E. Gamboa, J. L. Gomez-Skarmeta, and M. Kukuljan RE-1 silencer of transcription/neural restrictive silencer factor modulates ectodermal patterning during Xenopus development. J. Neurosci., March 8, 2006; 26(10): 2820 - 2829. [Abstract] [Full Text] [PDF]

				R. M. McCullough, C. R. Cantor, and C. Ding High-throughput alternative splicing quantification by primer extension and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry Nucleic Acids Res., June 20, 2005; 33(11): e99 - e99. [Abstract] [Full Text] [PDF]

				J. P. Venables Aberrant and Alternative Splicing in Cancer Cancer Res., November 1, 2004; 64(21): 7647 - 7654. [Abstract] [Full Text] [PDF]

				A. Roopra, Y. Huang, and R. Dingledine Neurological Disease: Listening to Gene Silencers Mol. Interv., October 1, 2001; 1(4): 219 - 228. [Abstract] [Full Text] [PDF]